Own CSL (ASX:CSL) shares? Here’s what to look for this reporting season

Why investors should keep an eye out for CSL’s plasma collections this reporting season.

| More on:
patient with doctor, medical company, medical insurance

Image source: Getty Images

The CSL Limited (ASX: CSL) share price has struggled to deliver shareholder value in 2021, with a year-to-date return of about 2.05%.

With August reporting season on the horizon, what should investors look out for in the company’s results?

All eyes on plasma collections

In CSL’s annual report to shareholders, it said “at the origins of our value chain, plasma donors fuel our pipeline …”.

Plasma collections form the backbone of many CSL treatments including its immunoglobulins business, which contributed approximately 43% of the group’s 1H21 revenue.

The last time CSL updated the market on its plasma collections was February, when the company released its FY21 half-year results.

It advised “plasma collections adversely impacted by COVID-19” and that collection volumes in December 2020 were roughly 80% of the December 2019 volumes.

The company launched multiple initiatives in an attempt to drive plasma collection figures. This included enhanced targeted marketing, improving the donor experience and the rollout of 29 new collection centres in FY21.

The CSL share price will be put to the test as to whether or not these initiatives are paying dividends.

CSL competitor notes recovery in plasma collections

The Motley Fool has previously covered observations of a plasma donation recovery in the United States.

Grifols, a US$14 billion Spanish multinational biotech company has observed some improvements in the plasma collections space.

In the company’s quarterly results on 4 May, it said, “In the United States, plasma donations are gradually recovering. Of note was the trend observed in January, February and April in the wake of the country’s vaccination rollouts and the easing of COVID-19 restrictions, while taking into account the mitigating effect of stimulus incentives issued in March and December.”

CSL share price tumbles on seemingly good results in February

It can be difficult to get a read on how the CSL share price will perform after the release of its full-year results on 18 August.

Looking back, the company delivered seemingly positive half-year results on 18 February with a 15% increase in revenue to US$4,911 million and a 44% jump in net profit after tax (NPAT) to US$1,248 million.

CSL acknowledged that COVID-19 had “tempered the performance of CSL Behring whilst boosting the performance of Seqirus”.

The company reaffirmed its (NPAT) guidance of US$2,170 million to US$2,265 million for FY21, which represents an increase of 3.2% to 7.7% on FY20 figures.

The CSL share price closed at $289.00 on 18 February and tumbled from there. It hit a year-to-date low of $246.00 on 8 March. The shares have since rallied to a year-to-date peak of $305.52, which it reached on 18 June.

At the time of writing today, the CSL share price is $290.53, up 1.94%.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares